ICER to assess treatment for smoking cessation

20 May 2025 - Report will be subject of Midwest CEPAC meeting in January 2026; draft scoping document open to ...

Read more →

ICER publishes protocol for first annual launch price and access report

19 May 2025 - Report to be issued in October 2025. ...

Read more →

ICER publishes final evidence report on treatment for retinitis pigmentosa

15 May 2025 - Independent appraisal committee voted that current evidence is adequate to demonstrate a net health benefit of ...

Read more →

Institute for Clinical and Economic Review to assess treatments for obesity management

29 April 2025 - Report will be subject of New England CEPAC meeting in November 2025; draft scoping document open ...

Read more →

ICER releases draft evidence report on treatment for secondary progressive multiple sclerosis

15 April 2025 - Public comment period now open until 13 May 2025; Requests to make oral comment during public ...

Read more →

ICER releases obesity medications white paper examining strategies to ensure affordable access

9 April 2025 - Paper analyses policy reforms and market actions to achieve affordable and equitable access for GLP-1 obesity ...

Read more →

ICER publishes final evidence report on treatment for acute pain

31 March 2025 - Independent appraisal committee vote was split on the net health benefit of suzetrigine compared to non-systemic ...

Read more →

ICER publishes evidence report on treatment for retinitis pigmentosa

26 March 2025 - There are significant uncertainties regarding long term efficacy and durability of sonpiretigene isteparvovec; ICER estimates that ...

Read more →

Health Economics Methods Advisory Group selects first area for study: assessing treatment benefits appropriate to consider in HTA decision-making

18 March 2025 -  The US based ICER, England’s NICE and Canada’s Drug Agency have selected the first research topic ...

Read more →

ICER to assess treatment for non-cystic fibrosis bronchiectasis

11 March 2025 - Report will be subject of CTAF meeting in September 2025; draft scoping document open to public ...

Read more →

ICER publishes special report on COPD therapies as part of CMS public comment process on Medicare drug price negotiations

3 March 2025 - Report reflects legislative specifications in the Inflation Reduction Act and subsequent CMS guidance. ...

Read more →

ICER releases draft evidence report on treatment for advanced retinitis pigmentosa

6 February 2025 - Public comment period now open until 6 March 2025; requests to make oral comment during public ...

Read more →

ICER publishes evidence report on treatment for acute pain

5 February 2025 - Current evidence suggests that suzetrigine may provide a net health benefit when compared to no systemic ...

Read more →

ICER announces new annual launch price and access report for 2025

22 January 2025 - New report will highlight opportunities to improve affordability and access, and demonstrate the importance of having ...

Read more →

ICER to assess treatments for spinal muscular atrophy

6 January 2025 - Report will be subject of Midwest CEPAC meeting in August 2025; draft scoping document open to ...

Read more →